

Corporate Risk Management



NHS Lanarkshire Board
31st January 2024

Subject: Corporate Risk Register Overview

1. Purpose

This paper is coming to the Board for:

For assurance		For endorsement		To note	X
---------------	--	-----------------	--	---------	---

2. Route to Board

This paper has been:

Prepared	X	Reviewed		Endorsed	
----------	---	----------	--	----------	--

By the Board Secretary, Corporate Business Manager and Corporate Management Team at its meeting held on 4th December 2023.

3. Background and Summary of Key Issues

Effective Risk Management is a fundamental cornerstone of good Corporate Governance and Internal Control and is an essential component in the delivery of the NHS Board's corporate objectives.

The NHS Lanarkshire corporate risk register is considered frequently by the corporate management team, who discuss new and emerging risks; very high graded risks across NHS Lanarkshire, mitigating controls and risks that exceed the corporate risk appetite.

The enclosed report (appendix 1) and the subsequent Corporate Risk Register in full (appendix 2) presents an update to the Corporate Risk Register for the reporting period November 2023 – January 2024.

Summary of material changes to the risks within the Corporate Risk Register. **For note** several of the following were previously reported to the Board in December 2023, due to an overlap in the reporting period. Changes to risk within the reporting period of this report are as follows:

- One risk was increased in terms of score: **2212** – Failure to Comply with NHS Sustainability Policy, DL (2021) 38
- Three risks were decreased in terms of score: **2126** – Sustaining Primary Care Out of Hours Service, **2155** – Impact of Unpredictable Public Health Outbreaks on Current Services (October 2023) and **2221** – Non-Compliance with Off-Framework DL (2023)5

For noting there were 2 changes to risk score for risk 2221 during this reporting period. Originally changed from Very High to Medium in October (November reporting period) and then subsequently reduced further from Medium to Low in December (January reporting period).

4. Strategic Context

This paper links to the following:

Corporate objectives	X	AOP		Government policy	
Government directive		Statutory requirement		AHF / local policy	
Urgent operational issue		Other		Corporate Governance	X

5. Contribution to Quality

This paper aligns to the following elements of safety and quality improvement:

Three Quality Ambitions:

Safe	X	Effective	X	Person Centred	X
------	---	-----------	---	----------------	---

6. Measures for Improvement

The presentation of these reports has been revised in line with the expectations of Non-Executives to use more infographics, and the reports will continue to evolve. Measures for improvement for each risk are captured in the controls and mitigation sections to reduce the impact and likelihood of each risk.

7. Financial Implications

All very high and high graded risks will be considered in terms of exceeding the corporate risk appetite against the adequacy of mitigating controls and action planning that might require a more intensive supported financial approach to mitigation.

8. Risk Assessment/Management Implications

No further risk analysis is required.

9. Fit with Best Value Criteria

This paper aligns to the following best value criteria:

Vision and leadership	X	Effective partnerships		Governance and accountability	X
Use of resources	X	Performance management	X	Equality	
Sustainability					

10. Equality and Diversity Impact Assessment

An E&D Impact Assessment has been completed

Yes
No

An equality and diversity impact assessment is not required for this report, as the approach applies equally.

11. Consultation and Engagement

This paper has been discussed and endorsed by CMT and prepared for onwards assurance to the Board.

12. Actions for the Board

The Board are asked to:

Approve		Endorse		Identify further actions	
Note	X	Accept the risk identified		Ask for a further report	

Board members are asked to:

- Consider the content of the attached report in Appendix 1 for approval.

13. Further Information

For further information about any aspect of this paper, please contact:

Mr P Cannon	Ms Allison Mclean	Professor J Gardner
Board Secretary	Corporate Business Manager	Chief Executive